slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,071-20,100
Pages 885
Rows per page 30
Arc
20,071-20,100 of 26,550
32
Uses a causal chain/process flow to link the board's actions to negative outcomes.jetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
33
Uses 'X' icons to emphasize negative actions by the target board.jetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
34
jetBlue | Mergers and Acquisitions Presentation Deck | 37 slidesjetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
35
The slide uses a checkmark icon list to emphasize key benefits and a dark blue callout box for the strategic thesis.jetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
36
jetBlue | Mergers and Acquisitions Presentation Deck | 37 slidesjetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
37
Uses a contrast-based argument to frame the merger benefits.jetBlue | Mergers and Acquisitions Presentation Deck | 37 slides · jetBlue
Activist deck Investment bank Beat · Solution1 hit
11
The chart illustrates the escalating mortality rates associated with different categories of drugs over time.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a shaded area for acute withdrawal and a dashed line for protracted withdrawal, mapped against time intervals for short-acting and long-acting opioids.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
13
The slide uses a simple process-flow diagram to categorize treatment options.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
The chart illustrates the divergence between OUD prevalence and treatment capacity over time (2003-2012).MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
The chart illustrates a clear divergence between maintenance and supervised withdrawal regarding the use of opioid agonists.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
16
Includes a citation of a specific academic paper on non-opioid neurotransmitter systems.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
17
The slide introduces a chemical compound (18-MC) and its relationship to ibogaine, highlighting a distinct mechanism of action and potential safety benefits.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
18
Source: Glick & Maisonneuve, 2000. The slide uses two different chart types (line and bar) to demonstrate the same pharmacological effect.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
19
The slide uses a bar chart to demonstrate the specificity of 18-MC compared to Ibogaine in a pharmacological study.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
20
Slide contains two distinct charts labeled A and B, referencing specific research papers.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
21
The slide displays 7 distinct bar charts representing different withdrawal symptoms (Weight Loss, Wet-Dog Shakes, Flinching, Grooming, Teeth Chattering, Burying, Diarrhea).MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
22
The chart highlights specific withdrawal symptoms (Wet-Dog Shakes, Teeth Chattering, Burying, Diarrhea) that show statistically significant reductions with 18-MC treatment.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
23
MindMed | Results Presentation Deck | 40 slidesMindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
24
The slide uses a 'So Why Now?' framing to justify the relevance of the topic.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
25
The table uses color coding (yellow for TBD/preclinical, green for established/favorable) to highlight the developmental status of 18-MC versus the established nature of Lofexidine.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · SolutionLoop · Trojan Horse1 hit
26
MindMed | Results Presentation Deck | 40 slidesMindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
27
The slide outlines a timeline of clinical trial events for the drug candidate MM-110.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
28
The slide uses a combination of a longitudinal bar/line chart and key metrics to quantify the problem.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
29
The slide uses a line chart metaphor to represent patient state/cravings over time, highlighting the intervention point of MM-110.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
30
The slide presents preclinical efficacy data for MM-110 using bar and line charts.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
31
The slide presents data from Rho & Glick (1998) showing dose-dependent reduction in withdrawal behaviors.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
32
The chart compares saline vs. Methoxycoronaridine (MM-110) across 6 time points (Base, Day 1, 2, 3, 6, 7).MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
33
MindMed | Results Presentation Deck | 40 slidesMindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Solution1 hit
34
SAD = Single Ascending Dose; MAD = Multiple Ascending Dose. Data shows n (%) of participants experiencing safety events.MindMed | Results Presentation Deck | 40 slides · MindMed
Conference presentation Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit